Insider transactions

Ulf Wiinberg

CIK 1187314 · Sr. VP&Pres. Wyeth Pharm EMEA · last filed 2026-09-02

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$578.1K
Companies
3
Total Filings
73
Lifetime Open-Market Net
-$6.72M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

WYE price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Related Filers
AGENUS INC — 47 joint filings, latest 2024-10-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
INKT Director 51,759 $10.43 $539.8K $27.6K 21 2026-09-02
AGEN Director 6,203 $6.16 $38.2K $207.7K 46 2024-10-03
WYETH (WYE) Delisted Sr. VP&Pres. Wyeth Pharm EMEA 71,498 — — -$6.96M 6 2008-04-29

Recent Filings · Page 4 of 8

73 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-09-19 INKT Grant (A) +10,688 $28.0K EDGAR
2022-07-21 INKT Buy (P) +20,000 $27.6K EDGAR
2022-07-06 AGEN Grant (A) — $0 EDGAR
2022-04-05 AGEN Grant (A) — $0 EDGAR
2022-03-11 INKT Grant (A) — $0 EDGAR
2022-02-08 AGEN Grant (A) — $0 EDGAR
2022-01-05 AGEN Grant (A) — $0 EDGAR
2021-10-05 AGEN Grant (A) — $0 EDGAR
2021-07-02 AGEN Grant (A) — $0 EDGAR
2021-06-21 AGEN Exer (M) +16,853 $0 EDGAR
Showing 31–40 of 73
Page 4 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.